KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors

Imatinib and other BCR-ABL1 inhibitors are effective therapies for chronic myeloid leukemia (CML), but these inhibitors target additional kinases including KIT, raising the question of whether off-target effects contribute to clinical efficacy. Based on its involvement in CML pathogenesis, we hypoth...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Corbin, Amie S., O’Hare, Thomas, Gu, Zhimin, Kraft, Ira L., Eiring, Anna M., Khorashad, Jamshid S., Pomicter, Anthony D., Zhang, Tian Y., Eide, Christopher A., Manley, Paul W., Cortes, Jorge E., Druker, Brian J., Deininger, Michael W.
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3894913/
https://ncbi.nlm.nih.gov/pubmed/23887971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-1318
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares